

**PCR-/NAT *Helicobacter pylori*
 (RV 533) April 2011**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1115331	+	61/72	<i>Helicobacter pylori</i> (~ 1x10 ³ CFU/mL) Clarithromycin susceptible (wildtype 28S rDNA sequence)
1115332	+++	61/72	<i>Helicobacter pylori</i> (~ 1x10 ⁵ CFU/mL) Clarithromycin susceptible (wildtype 28S rDNA sequence)
1115333	++	61/72	<i>Helicobacter pylori</i> (~ 1x10 ⁴ CFU/mL) Clarithromycin susceptible (wildtype 28S rDNA sequence)
1115334	Ø	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

<i>n = 44</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1115331	1115332	1115333	1115334	1115331	1115332	1115333	1115334	
Befund Result									
Positiv	35 ¹⁾	44 ¹⁾	43 ¹⁾	0	n.d.	1	1	1	1
Negativ	9	0	1	44	nein no	43	43	43	43
Fraglich Questionable	0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.
Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Commercial assay [27] (n = 14)	40	40 / 42	95	14	14 / 14	100
In house PCR assay [28] (n = 27)	74	74 / 81	91	27	27 / 27	100
Andere / k.A. / other [29] (n = 3)	8	8 / 9	89	3	3 / 3	100

Comments: ¹⁾ Twenty-nine of the 44 participants reported results for molecular Clarithromycin-susceptibility testing. With the exception of 2 laboratories, all reported results were correct.